Perriman Damien Alan 4

What Happened
Damien Perriman, Chief Commercial Officer of ExoZymes Inc. (EXOZ), was granted 8,887 shares on April 1, 2026. The reported acquisition price was $8.44 per share, for a total value of approximately $75,006. This was an award/grant (Form 4 transaction code "A"), which is an acquisition rather than an open-market purchase.

Key Details

• Transaction date: 2026-04-01
• Transaction type/code: Award/Grant (A)
• Shares issued/acquired: 8,887
• Price per share reported: $8.44
• Total reported value: ~$75,006 (8,887 × $8.44 = $75,005.28)
• Shares owned after transaction: Not specified in the Form 4 filing
• Filing date: 2026-04-08 — filed 7 days after the transaction (later than the typical 2-business-day Form 4 deadline)

Context
Grants and awards are a common form of executive compensation and do not, by themselves, indicate a buy/sell decision about the stock. The filing does not specify vesting terms, whether the shares are restricted or immediately transferable, or any tax-withholding details. Note that the Form 4 was filed after the usual 2-business-day window, which makes the disclosure less timely for investors tracking insider activity.